NPS Pharmaceuticals Inc

NPS Pharmaceuticals — Merger or Acquisition (April 2003)

10 slides from NPS Pharmaceuticals's merger presentation, Apr 9, 2003

  1. Slide 1: Science, Pipeline, Products: Creating a Biotechnology Leader

    Science, Pipeline, Products: Creating a Biotechnology Leader

  2. Slide 2: To Build a Sustainable Top-Tier Biotech Based On:

    To Build a Sustainable Top-Tier Biotech Based On: • A deep, diversified and sustainable pipeline • A clearly defined pathway to profitability • A fully integrated infrastructure and stable financial position

  3. Slide 3: Platform Technologies and Pipeline

    Platform Technologies Preclinical Phase! Phase Il Phase Ill + PEG- fk + Single-Chain ; Antibodies crtoke + Inhaled Leuprolicie P Commercialization & Manufacturing + PEG-INTRON + ABELCET + ADAGEN + ONCASPAR * DEPOCYT NPS mmm ENZON

  4. Slide 4: Pipeline, Products & Technologies

    Pipeline, Products & Technologies

  5. Slide 5: ABELCET, ONCASPAR, DEPOCYT, ADAGEN

    • ABELCET ® • ONCASPAR ® • DEPOCYT ® • ADAGEN ®

  6. Slide 6: PREOS Cinacalcet HCl

    PREOS TM Cinacalcet HCI

  7. Slide 7: Market opportunity (U.S.)

    • Market opportunity (U.S.) — Primary HPT 500,000 patients — Secondary HPT 280,000 dialysis patients — Secondary HPT 800,000 predialysis patients

  8. Slide 8: Operational Overview

    Operational Overview

  9. Slide 9: Locations

    Locations Manufacturing: Indianapolis, IN Research: /Toronto, Canada _ Manufacturing: Toronto, Canada Research: Piscataway, NJ Manufacturing: South Plainfield, NJ Headquarters: Research: Bridgewater, NU Salt Lake City, Utah

  10. Slide 10: Science, Pipeline, Products: Creating a Biotechnology Leader

    Science, Pipeline, Products: Creating a Biotechnology Leader

NPS Pharmaceuticals — Merger or Acquisition (April 2003) on 6ix